Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Telehealth company Hims & Hers is being called out over its Super Bowl ad going after Big Pharma and popular weight-loss ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...

Even folks who aren't into football tune into the Super Bowl for its ads, but this year there's some "big drama" around one ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care products.Hims is part of Hims & Hers Health, a publicly-traded company ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Shares of Hims & Hers (HIMS) have jumped on Friday as the company is preparing to air its first Super Bowl ad promoting its compounded ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...